- Starpharma ( SPL ) spent the September quarter advancing its DEP technology and signing a new research agreement
- In mid-August, the company signed a new DEP research agreement with MSD to develop and synthesize a range of DEP-dendrimer conjugates for MSD to test and characterize
- In September, SPL presented promising antitumor activity data in prostate cancer at the ESMO Congress
- Starpharma spent $7.28 million during the quarter and invested $101,000 in property, plant and equipment
- As of Sept. 30, Starpharma had $42.71 million in total available funding, representing 5.9 quarters of utilization if expense levels remain unchanged.
- The company’s shares fell 5.25 percent to end the day at 54 cents
Starpharma ( SPL ) spent the September quarter advancing its DEP technology and signing a new research agreement.
In mid-August, the company named after signed a new DEP science agreement with MSDtrade name of Merck Sharp & Dohme.
We will see the agreement Starpharma develops and synthesizes a range of DEP dendrimer conjugates for MSDs for testing and characterization.
Starpharma’s DEP technology works as a drug delivery mechanism to ensure that drugs are delivered to the right part of the body at the right time.
In September Starfarm presented promising data on antitumor activity on prostate cancer at the European Society of Medical Oncology (ESMO) Congress in Paris.
The data showed that cabazitaxel DEP has many key advantages, including superior efficacy, longer progression-free survival, and a lower incidence of major side effects.
next, Phase II September trials of DEP irinotecan and DEP docetaxel are progressing well, enrolling 83 and 74 patients, respectively.
“We were very pleased to present new clinical results at the ESMO Congress in Paris during the quarter, which highlighted longer progression-free survival and a lower incidence of key adverse events in patients treated with DEP cabazitaxel compared to previously published data for conventional cabazitaxel,” said the general director. Dr. Jackie Fairley commented.
“This quarter, Starpharma also expanded its relationship with MSD through a second DEP
The ADC agreement builds on our current first program which started in 2021.”
Looking at the financials, Starpharma burned through $7.28 million, most of which went into research and development.
The company also invested $101,000 in property, plant and equipment.
As of Sept. 30, Starpharma had $42.71 million in total available funding, representing 5.9 quarters of utilization if expense levels remain unchanged.
The company’s shares fell 5.26 percent to end the trading day at 54 cents.